Profile | GDS2987 / GI_4502832-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 3.6 | 13 |
GSM215244 | HMVEC_vehicle_rep2 | 6 | 16 |
GSM215253 | HMVEC_vehicle_rep3 | 7.1 | 24 |
GSM215254 | HMVEC_atorvastatin_rep1 | 7 | 19 |
GSM215282 | HMVEC_atorvastatin_rep3 | 19.1 | 41 |
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 25.9 | 45 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 23.2 | 43 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 14.7 | 24 |
GSM215294 | HMVEC_SLx2119_rep1 | 26.2 | 62 |
GSM215295 | HMVEC_SLx2119_rep2 | 4.7 | 10 |
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 67.3 | 67 |
GSM215298 | PASMC_vehicle_rep2 | 33.9 | 47 |
GSM215310 | PASMC_vehicle_rep3 | 27.8 | 41 |
GSM215311 | PASMC_atorvastatin_rep1 | 59 | 67 |
GSM215312 | PASMC_atorvastatin_rep2 | 77.7 | 70 |
GSM215313 | PASMC_atorvastatin_rep3 | 20 | 29 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 13.3 | 23 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 23.2 | 41 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 5.1 | 9 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | ||
GSM215329 | PASMC_SLx2119_rep3 | 15.7 | 30 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 11.7 | 32 |
GSM215332 | Fibroblasts_vehicle_rep3 | 0.6 | 2 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 20.7 | 48 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | 17.2 | 40 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 1.1 | 4 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 22.1 | 55 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 13.9 | 37 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 6.8 | 20 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 21.3 | 50 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 28.3 | 56 |